HRP20110643T1 - Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista - Google Patents

Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista Download PDF

Info

Publication number
HRP20110643T1
HRP20110643T1 HR20110643T HRP20110643T HRP20110643T1 HR P20110643 T1 HRP20110643 T1 HR P20110643T1 HR 20110643 T HR20110643 T HR 20110643T HR P20110643 T HRP20110643 T HR P20110643T HR P20110643 T1 HRP20110643 T1 HR P20110643T1
Authority
HR
Croatia
Prior art keywords
growth factor
factor receptor
hepatocyte growth
ipt
cancer
Prior art date
Application number
HR20110643T
Other languages
English (en)
Croatian (hr)
Inventor
Maria Comoglio Paolo
Carminati Paolo
Michieli Paolo
Basilico Cristina
Original Assignee
Metheresis Translational Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Research Sa filed Critical Metheresis Translational Research Sa
Publication of HRP20110643T1 publication Critical patent/HRP20110643T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20110643T 2008-05-14 2011-09-07 Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista HRP20110643T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08103958 2008-05-14

Publications (1)

Publication Number Publication Date
HRP20110643T1 true HRP20110643T1 (hr) 2011-10-31

Family

ID=40984839

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110643T HRP20110643T1 (hr) 2008-05-14 2011-09-07 Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista

Country Status (18)

Country Link
US (4) US8404453B2 (es)
EP (1) EP2119448B1 (es)
JP (1) JP5623027B2 (es)
KR (1) KR101509263B1 (es)
AT (1) ATE513556T1 (es)
BR (1) BRPI0901502A2 (es)
CA (1) CA2665958C (es)
CY (1) CY1111853T1 (es)
DK (1) DK2119448T3 (es)
EA (1) EA017863B1 (es)
ES (1) ES2368603T3 (es)
HR (1) HRP20110643T1 (es)
IL (1) IL198545A0 (es)
MX (1) MX2009005049A (es)
PL (1) PL2119448T3 (es)
PT (1) PT2119448E (es)
SG (1) SG157312A1 (es)
SI (1) SI2119448T1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
US20150147274A1 (en) * 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
CN107002133B (zh) * 2014-11-20 2022-07-05 天主教大学基金会 Met的新型自活化且细胞内的突变体
WO2018062402A1 (en) 2016-09-29 2018-04-05 Mitsubishi Tanabe Pharma Corporation Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
CN113567685B (zh) * 2021-09-26 2022-05-17 瑞博奥(广州)生物科技股份有限公司 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520158A1 (en) * 1991-05-10 1992-12-30 PHARMACIA S.p.A. Truncated forms of the hepatocyte growth factor (HGF) receptor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2760602A (en) 2001-03-23 2002-09-26 Agouron Pharmaceuticals, Inc. Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2005108424A1 (en) 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
ES2561155T3 (es) * 2005-07-28 2016-02-24 Anges Mg, Inc. Promotor de la linfangiogénesis
AU2006296171A1 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
KR101429297B1 (ko) * 2006-02-06 2014-08-12 메테레시스 트랜스레이셔날 리서치 에스.에이. 종양 치료를 위한 항-Met 단클론 항체, 이의 단편과벡터 및 상응하는 산물
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof

Also Published As

Publication number Publication date
CA2665958A1 (en) 2009-11-14
EA017863B1 (ru) 2013-03-29
SI2119448T1 (sl) 2012-02-29
CA2665958C (en) 2014-01-07
US20120115219A1 (en) 2012-05-10
JP5623027B2 (ja) 2014-11-12
JP2009291191A (ja) 2009-12-17
SG157312A1 (en) 2009-12-29
ATE513556T1 (de) 2011-07-15
PL2119448T3 (pl) 2011-11-30
AU2009201893A1 (en) 2009-12-03
US8404453B2 (en) 2013-03-26
IL198545A0 (en) 2011-07-31
US20120108789A1 (en) 2012-05-03
BRPI0901502A2 (pt) 2010-01-26
US20090298079A1 (en) 2009-12-03
CY1111853T1 (el) 2015-11-04
MX2009005049A (es) 2009-12-18
ES2368603T3 (es) 2011-11-18
PT2119448E (pt) 2011-09-27
DK2119448T3 (da) 2011-09-26
US20130183690A1 (en) 2013-07-18
KR20090118846A (ko) 2009-11-18
US9121854B2 (en) 2015-09-01
EP2119448B1 (en) 2011-06-22
KR101509263B1 (ko) 2015-04-06
EP2119448A1 (en) 2009-11-18
EA200900537A1 (ru) 2009-12-30
US9310377B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
HRP20110643T1 (hr) Mjesto vezanja visokog afiniteta za receptor faktora rasta hepatocita (hgfr) i postupci za identifikaciju njegovih antagonista
Croset et al. miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes
Li et al. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization
Goel et al. Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells
Tung et al. Chloride intracellular channel 1 functions in endothelial cell growth and migration
Njah et al. A role of agrin in maintaining the stability of vascular endothelial growth factor receptor-2 during tumor angiogenesis
JP2009291191A5 (es)
Brodsky et al. 5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons
Ma et al. LncRNA MALAT1 knockdown inhibits cell migration and invasion by suppressing autophagy through miR-384/GOLM1 axis in glioma.
Lang et al. The renin-angiotensin system mediates hyperoxia-induced collagen production in human lung fibroblasts
Park et al. High expression of large-conductance Ca2+-activated K+ channel in the CD133+ subpopulation of SH-SY5Y neuroblastoma cells
Gao Biology of Vascular Smooth Muscle
JP2009539377A5 (es)
Lim et al. Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430
Wang et al. FERM-containing protein FRMD5 is a p120-catenin interacting protein that regulates tumor progression
WO2021195446A2 (en) Methods and compositions for restoring stmn2 levels
Nassar et al. Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis
Wang et al. CircNDC80 promotes glioblastoma multiforme tumorigenesis via the miR-139-5p/ECE1 pathway
Zeitlmayr et al. TRPM7 restrains plasmin activity and promotes transforming growth factor-β1 signaling in primary human lung fibroblasts
Rimmaudo et al. Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis
Sadej et al. Tenascin C interacts with ecto-5′-nucleotidase (eN) and regulates adenosine generation in cancer cells
He et al. TINCR inhibits the proliferation and invasion of laryngeal squamous cell carcinoma by regulating miR-210/BTG2
Yao et al. Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells
Klosek et al. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells
Denelavas et al. Real-time cellular impedance measurements detect Ca2+ channel-dependent oscillations of morphology in human H295R adrenoma cells